Patient organization exploring development of a multi-stakeholder forum on real world evidence that, among other things, could address research questions posed by the Centers for Medicare and Medicaid Services in its national coverage determination for Alzheimer’s drugs. Read more here.
Virtual Public Forum
Tuesday, June 14, 2022
1-3pm Eastern Time
More than 200 patient, consumer, industry, research, and government stakeholders joined the Foundation’s Annual Public Meeting of our Board of Directors on May 16, 2022. The event featured candid discussions with senior FDA leadership on topics ranging from data interoperability, food safety, and FDA’s plans for a return to in-person events. See highlights from the meeting below.
If the proposed Advanced Research Projects Agency for Health is created, new treatment candidates would need to engage with FDA early on to help determine appropriate clinical testing design, FDA principal deputy commissioner Janet Woodcock said Monday at the Reagan Udall Foundation for the FDA’s annual public board of directors meeting. Read more here.
This month we will learn more about the opportunity to ‘listen’ for safety signals in social media from the Sanofi Digital team, as they share some of their advanced analytics and visualization regarding what is being said about COVID vaccine safety, with a particular focus on children.
In this month's Diagnostics Lab meeting, we will be hearing from two groups working to enable the flow of health information throughout numerous vendors, implementers, networks and governance frameworks. We’ll hear first from Mariann Yeager, CEO of The Sequoia Project which works closely with the Office of the National Coordinator for Health IT to identify and clear the barriers to interoperability at a national level.
Global Genes, a leading rare disease patient advocacy organization, today announced its 7th annual
Each year, the Reagan-Udall Foundation for the FDA conducts an Annual Public Meeting of its Board of Directors to share its activities in support of the U.S. Food and Drug Administration. This meeting is open to the public, but advanced registration is required.
Commissioner Robert M. Califf, MD, highlighted FDA's key priorities.
